The FDA asked for help last week on some housecleaning it must do under President Donald Trump’s regulatory agenda.
The agency issued notices in the Federal Register seeking suggestions on what regulations it could cut or replace to comply with Trump’s January executive order on reducing regulations and controlling regulatory costs.
Trump’s plan is a two-for-one special: Every time an agency proposes or issues a new regulation, it must identify at least two existing ones to be repealed. And the costs new regulations will impose must be fully offset by the costs of the regulations being cut.
The FDA’s notices asked the public for advice on identifying drug, medical device, and biologics regulations it could target, as well as regulations in all other areas. The agency says it wants comments on which ones are outdated, unnecessary, or overly burdensome.
The administration’s mandate isn’t a burden on the agency, according to Anna Abram, the FDA’s deputy commissioner for policy, planning, legislation, and analysis. She painted the effort in a positive light, noting in a blog post the agency is over 100 years old, and its regulations need updating.
“Some have been in place for decades, and may not reflect the most up-to-date approach to achieving our public health mission,” she wrote. She said existing rules may hinder generic drug competition, for example.
Public interest groups like Public Citizen are skeptical. A similar review took place under the Obama administration, Public Citizen regulatory policy advocate Amit Narang said, leaving effective regulations on the chopping block.
Read my story here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)